AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 161 min read$CMND

HRT FINANCIAL LP sold $7K of CMND

HRT FINANCIAL LP sold 2,102 shares of Clearmind Medicine Inc. (CMND) at $3.36 on 2026-06-12.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 16, 2026, 1:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CMND
Neutral
high confidence
Mentioned
$CMND
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDNeutralLow
01

Why it matters

The disclosure updates ownership/flow information but does not introduce new company performance, regulatory, or product catalysts.

02

Market read

Traders may monitor for sentiment impact from insider selling, but the filing alone is unlikely to drive a sustained repricing without additional fundamentals.

03

What to watch

The article provides only the sale size/price and post-transaction holdings; it does not indicate whether other insiders or the company have concurrent news.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-16; sale dated 2026-06-12

Background

SEC Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDNeutralHigh confidence
Context

HRT Financial LP, a 10% owner, filed an SEC Form 4 selling 2,102 CMND shares at $3.3600 on 2026-06-12.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a disclosed open-market sale with no accompanying company-specific catalyst, guidance, or operational change.

Market effects

Sector

No sector read-through; this is a single-company ownership transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10% owner sale can be planned liquidity rather than a bearish signal, especially with no 10b5-1 plan stated.

Key entities

  • issuer
    Clearmind Medicine Inc.

    Subject of the Form 4 insider transaction; ticker CMND.

  • insider
    HRT Financial LP

    10% owner who executed an open-market sale of CMND shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
MAY 29
$CMNDMedAI 9/10

Clearmind Medicine Shares Jump 47% After Japan Patent Filing For Depression Treatment

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published covering compositions using 5-Methoxy-2-aminoindan (MEAI) for depression treatment. The filing, the company said, adds to its intellectual property portfolio for non-hallucinogenic neuroplastogen-derived therapeutics. Volume was 41.05 million shares versus 612,955 average.

rttnews.com3 min